We're in an era of development and innovation in biotech, says WSJ's Greg Zuckerman

Greg Zuckerman, special writer at the Wall Street Journal, joins the 'Halftime Report' to discuss why Moderna and Pfizer's underperformance in the markets are causing hedge funds to lose money.